Page 147 - உயிர் அறிவியல் வரையறுக்கப்பட்டவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Se registra nuevo caso de PIMS en Biobío: Menor de 9 años se encuentra en la UCI del Hospital de Los Ángeles
elmostrador.cl - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from elmostrador.cl Daily Mail and Mail on Sunday newspapers.
ESTE MARTES 13 DE ABRIL NOS ENCONTRAMOS CON NUESTROS MÚSICOS Y MÚSICAS DE ÑUBLE Y BÍO BÍO – SCD
scd.cl - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scd.cl Daily Mail and Mail on Sunday newspapers.
Advertisement
JGC HOLDINGS CORPORATION (Representative Director, Chairman and CEO Masayuki Sato) have announced that JGC JAPAN CORPORATION (Representative Director and President Shoji Yamada), which operates the domestic EPC business of the JGC Group, has been awarded an order for the design, procurement and construction of a biomass power generation plant project in Miyagino Ward, Sendai City, Miyagi Prefecture, Japan.
The project is for Sendai-ko Biomass Power GK., owned by Sumitomo Corporation Group, and calls for the new construction of a biomass power generation facility with an output of approximately 112 MW. The plant is to be fuelled by woody pellets and chips.
By Reuters Staff
1 Min Read
FILE PHOTO: Vials labelled COVID-19 Coronavirus Vaccine and sryinge are seen in front of displayed Johnson&Johnson logo in this illustration taken, February 9, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
(Reuters) - Emergent BioSolutions Inc said late on Sunday that a key U.S. agency has increased an order, related to the manufacturing of Johnson & Johnson’s COVID-19 vaccine, by $23 million.
The amount will be used to purchase biologics equipment specific to J&J’s vaccine and support the potential manufacturing expansion at the company’s Baltimore Bayview facility, the company said in a statement.
Emergent also said that it will agree to a mutual ramp down of manufacturing of AstraZeneca Plc’s COVID-19 vaccine bulk drug substance.
vimarsana © 2020. All Rights Reserved.